Xiaoli Feng

机构：Nanjing University of Chinese Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Southern Medical University

发表论文 56 篇 · 总被引 2755 次 · h-index 21

代表论文

• KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer (2022 · 癌症：英文版 · 被引 183)
• A non‐metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11‐mediated CD133 stability (2022 · 癌症：英文版 · 被引 90)
• Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer (2022 · BMC Medicine · 被引 90)
• Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators (2024 · Cancer Cell · 被引 57)
• Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer (2020 · Cancer Biology and Medicine · 被引 52)
• Rapid generation of ACE2 humanized inbred mouse model for COVID-19 with tetraploid complementation (2020 · National Science Review · 被引 34)